(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the healthcare investment community.
The company is scheduled to join the Wolfe Research Healthcare Conference 2025 in New York, where it will host a fireside chat on Tuesday, November 18, at 8:40 AM ET.
PacBio will also attend the Jefferies Global Healthcare Conference in London on Wednesday, November 19, conducting one-on-one meetings with investors.
In addition, the company will present at the Stephens Annual Investment Conference in Nashville, TN, with a fireside chat planned for Wednesday, November 19, at 10:00 AM CT.
PacBio designs, develops, and manufactures advanced sequencing solutions that help scientists and clinical researchers resolve genetically complex problems.
The company's portfolio includes the Revio systems, a high-throughput long-read sequencing platform designed for population-scale genomics, and the Vega system, a benchtop sequencer optimized for accessibility and smaller-scale studies. Its flagship HiFi long-read sequencing technology combines the completeness of long reads with the accuracy of short reads, enabling applications across human genomics, plant and animal sciences, infectious disease, microbiology, oncology, and other emerging fields.
For the third quarter ended September 30, 2025, the company reported total revenue of $38.4 million, compared to $40 million in the prior-year quarter.
GAAP gross profit for Q3 2025 was $15.9 million, up from $10 million in Q3 2024, while the non-GAAP gross margin expanded to 42% from 33% a year earlier.
Net loss narrowed to $38 million, or $0.13 per share, compared to $60.7 million, or $0.22 per share, in the prior-year quarter.
The company ended the quarter with $298.7 million in cash, cash equivalents, and investments, providing a solid foundation to support ongoing development. Looking ahead, PacBio highlighted several milestones:
The company introduced its new SPRQ-Nx sequencing chemistry, expected to lower sequencing costs by up to 40% and enable high acuracy genomes for under $300 at scale.
It also received regulatory approval in China for the Sequel II CNDx system, launched expanded PureTarget HiFi assays, and noted adoption of its Revio systems in major studies including the National Institute on Aging's Long Life Family Study and the Korean Pangenome Reference Project.
The Revio system was selected for the National Institute on Aging's Long Life Family Study to sequence up to 7,800 whole genomes and epigenomes.
In the third quarter of 2025, PacBio sold 13 Revio systems and 32 Vega systems, contributing to instrument revenue of $11.3 million. Management said these advances position PacBio's technology to be economically competitive with short-read sequencing platforms.
PACB has traded in the range of $0.58 to $2.46 over the past year. The stock closed Friday (November 14, 2025) at $1.61, down 1.23%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
